ArticleMolecular biology reports2026
Emerging miRNA biomarkers in breast cancer: The role of miR-223, miR-326, and miR-429 in tumor profiling.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveGlobally, breast cancer (BC) continues to be the primary cause of cancer-related death for women, underscoring the need for reliable biomarkers for early detection and improved patient outcomes. Because of their stability in biological fluids and their functions in controlling gene expression, microRNAs (miRNAs) have become attractive diagnostic tools. MATERIALS AND
methodsWith the hope of identifying new diagnostic biomarkers, this study attempted to study miR-223, miR-326, and miR-429 expression patterns in BC patients. Here, we used quantitative real-time PCR (qRT-PCR) to examine the miRNA expression levels in serum samples taken from 64 BC patients and 64 healthy controls.
resultsIn comparison to controls, BC patients showed a substantial decrease in miR-223 and miR-326 and an increase in miR-429 (p < 0.05). With an AUC of 0.88, sensitivity of 76%, and specificity of 78%, miR-326 showed the best diagnostic accuracy according to the Receiver Operating Characteristic (ROC) curve analysis. Although there was no obvious connection between miRNA expression and clinical characteristics like tumor size, lymph node metastases, or TNM stage, a notable association was observed between miRNA expression and body mass index (BMI), with higher expression levels in obese patients (p < 0.05).
conclusionAccording to these findings, miR-223, miR-326, and miR-429, particularly miR-326, hold promise as diagnostic biomarkers for BC. Further studies with larger cohorts and functional validation are warranted to confirm their diagnostic utility and explore their roles in BC pathogenesis.
Indexed as
Identifiers
41920379What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.